Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders ...

Alpha Cognition licenses Zunveyl to China Medical System for $44M, covering Asia (excl. Japan), Australia, and New Zealand. ALPHA-1062 shows promise in reducing neuroinflammation and ...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing ...

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company offers ...

Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and commercialization of Zunveyl in Asia, Australia and New Zealand.

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company ...

Alpha Cognition remains on track to launch Zunveyl in the United States in Q1 2025. The company will provide a corporate update and present its Launch Strategy on January 28, 2025.